The effect of ticagrelor on myocardial microcirculation, cardiac function, and adverse cardiovascular events in STEMI patients after PCI

被引:1
|
作者
Liu, D. -L. [1 ]
Bao, W. -W. [1 ]
Zeng, X. -M. [2 ]
Liu, X. -T. [1 ]
Zhang, Z. [1 ]
机构
[1] 900th Hosp Joint Logist Support Force PLA, Dept Med & Hlth, Fuzhou, Peoples R China
[2] Fujian Prov Judicial Drug Addict Hosp, Dept Internal Med, Fuzhou, Peoples R China
关键词
ST-segment elevation myocardial infarction; Percu-taneous coronary intervention; Cardiac function; Tica-grelor; Adverse cardiovascular events; PERCUTANEOUS CORONARY INTERVENTION; INFARCTION; CLOPIDOGREL; INJECTION; TIROFIBAN; OUTCOMES;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
<bold>Objective: </bold>This study aimed to investigate the effects of ticagrelor on myocardial microcirculation, cardiac function, and adverse cardiovascular events in ST-segment elevation myocardial infarction (STEMI) patients after percutaneous coronary intervention (PCI).<bold>Patients and methods: </bold>A total of 80 STEMI patients admitted to our hospital from February 2020 to March 2023 were selected and included in the retrospective study, all receiving PCI treatment. They were randomly and retrospectively divided into a control group (40 cases) and an observation group (40 cases), and treated with clopidogrel and ticagrelor, respectively. The clinical effects were compared.<bold>Results: </bold>The starting perfusion time of the contrast agent in the myocardial infarction area in the observation group was 2.22 +/- 0.27 s, and the peak perfusion time was 2.62 +/- 0.27 s, which was lower than those in the control group (2.51 +/- 0.29 s and 3.21 +/- 0.39 s, t=4.629, 7.867, p=0.000). The ratio of peak perfusion intensity between the two groups was significantly different (t=2.363, p=0.021). Left ventricular ejection fraction, stroke volume index, and cardiac index in the observation group were higher than those in the control group (55.03 +/- 6.03 vs. 52.33 +/- 5.13; 57.39 +/- 6.81 vs. 51.11 +/- 6.31 L/min<middle dot>m-2; 3.49 +/- 0.45 vs. 3.12 +/- 0.38 mL/m2, t=2.157, 4.278, 3.973, p<0.05). The observation group had lower levels of brain natriuretic peptide and C-reactive protein compared to the control group (425.35 +/- 55.71 vs. 589.36 +/- 70.24 pg/mL; 15.13 +/- 1.03 vs. 21.64 +/- 2.74 mg/L; t=11.570, 14.066, p=0.000). There was no statistical significance in the incidence of adverse cardiovascular events between the two groups (2.50% vs. 7.50%, chi 2=1.920, p=0.166).<bold>Conclusions: </bold>The use of ticagrelor can regulate myocardial microcirculation and improve cardiac function in STEMI patients undergoing PCI.
引用
收藏
页码:9781 / 9787
页数:7
相关论文
共 50 条
  • [41] Prediction of no-reflow and major adverse cardiovascular events with a new scoring system in STEMI patients
    Bayramoglu, Adil
    Tasolar, Hakan
    Kaya, Ahmet
    Tanboga, Ibrahim Halil
    Yaman, Mehmet
    Bektas, Osman
    Gunaydin, Zeki Yuksel
    Oduncu, Vecih
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2018, 31 (02) : 144 - 149
  • [42] Risk of Adverse Cardiovascular Events in Cardiac Sarcoidosis Independent of Left Ventricular Function
    Rosenthal, David G.
    Cheng, Richard K.
    Petek, Bradley J.
    Masri, Sofia Carolina
    Mikacenic, Carmen
    Raghu, Ganesh
    Patton, Kristen K.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 127 : 142 - 148
  • [43] Effect of aspirin and clopidogrel response on PCI-related myocardial infarction and six-month major adverse cardiac events
    Eshtehardi, P.
    Windecker, S.
    Hess, O. M.
    Cook, S.
    Billinger, M.
    Togni, M.
    Vogel, R.
    Seiler, C.
    Meier, B.
    Wenaweser, P.
    EUROPEAN HEART JOURNAL, 2008, 29 : 832 - 832
  • [44] Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI)
    Tu, Yanming
    Zhang, Jingyi
    Zhang, Ming
    Li, Zhiyong
    Zong, Wenxia
    Zhou, Qiyu
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 34 (05) : 2035 - 2040
  • [45] The relationship between low thiol levels and major adverse cardiovascular events after primary percutaneous coronary intervention in patients with STEMI
    Akkus, Oguz
    Topuz, Mustafa
    Koca, Hasan
    Harbalioglu, Hazar
    Kaypakli, Onur
    Kaplan, Mehmet
    Sen, Omer
    Bulut, Atilla
    Celik, Hakim
    Erel, Ozcan
    Gur, Mustafa
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2018, 46 (04): : 248 - 259
  • [46] ADVERSE EVENTS AFTER PULMONARY FUNCTION TESTING WITH RECENT MYOCARDIAL INFARCTION
    Altree, T.
    Bussell, L.
    Nguyen, P.
    Johnston, S.
    RESPIROLOGY, 2019, 24 : 195 - 195
  • [47] Myocardial Strain Predicts Adverse Cardiac Events in Patients Treated with Anthracyclines
    Ali, Mohammed T.
    Yucel, Evin
    Bouras, Souhila
    Scherrer-Crosbie, Marielle
    CIRCULATION, 2014, 130
  • [48] ASSOCIATION OF MYOCARDIAL INJURY BIOMARKERS AND CARDIOVASCULAR MAGNETIC RESONANCE PARAMETERS IN STEMI PATIENTS TREATED WITH PRIMARY PCI
    Virbickiene, A.
    Padervinskiene, L.
    Kreckauskiene, R.
    Bucius, P.
    Jureviciute, J.
    Jankauskas, A.
    Gustiene, O.
    Lapinskas, T.
    ATHEROSCLEROSIS, 2022, 355 : E121 - E121
  • [49] Effects (MACE and bleeding events) of ticagrelor combined with omeprazole on patients with acute myocardial infarction undergoing primary PCI
    Zhang, Fucheng
    Su, Shuhong
    Hou, Yuyan
    Zhao, Lipei
    Wang, Zhifang
    Liu, Fen
    Wu, Fengli
    Zhang, Li
    HELLENIC JOURNAL OF CARDIOLOGY, 2020, 61 (05) : 306 - 310
  • [50] Immature platelets as a novel biomarker for adverse cardiovascular events in patients after non-cardiac surgery
    Anetsberger, Aida
    Blobner, Manfred
    HaIler, Bernhard
    Schmid, Sebastian
    Umgelter, Katrin
    Hager, Theresa
    Langgartner, Clemens
    Kochs, Eberhard F.
    Laugwitz, Karl-Ludwig
    Jungwirth, Bettina
    Bernlochner, Isabel
    THROMBOSIS AND HAEMOSTASIS, 2017, 117 (10) : 1887 - 1895